Molecular CellMolecular BiologyPeer-reviewed journal article
PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, andRNA polymerase pause release at select gene targets
Susu ZhangiD, Jing WangiD, Qi LiuiD, William Hayes McDonaldiD, Monica L. BomberiD, Hillary M. LaydeniD, Jacob D. Ellis, Scott C. BorinsteiniD, Scott W. HiebertiD, Kristy R. StengeliD
Abstract
Transcriptional control is a highly dynamic process that changes rapidly in response to various cellular and extracellular cues1. Thus, it is difficult to achieve a mechanistic understanding of transcription factor function using traditional genetic deletion or RNAi methods, because these slow approaches make it challenging to distinguish direct from indirect transcriptional effects. Here, we used a chemical-genetic approach to rapidly degrade a canonical transcriptional activator, PAX3-FOXO12-6 to define how the t(2;13)(q35;q14) disrupts normal gene expression programs to trigger cancer. By coupling rapid protein degradation with the analysis of nascent transcription over short time courses, we identified a core transcriptional network that rapidly collapsed upon PAX3-FOXO1 degradation. Moreover, loss of PAX3-FOXO1 impaired RNA polymerase pause release and transcription elongation at regulated gene targets. The activity of PAX3-FOXO1 at enhancers controlling this core network was surprisingly selective and often only a single element within a complex super-enhancer was affected. In addition, fusion of the endogenous PAX3-FOXO1 with APEX2 identified proteins in close proximity with PAX3-FOXO1, including ARID1A and MYOD1. We found that continued expression of PAX3-FOXO1 was required to maintain chromatin accessibility and allow neighboring DNA binding proteins and chromatin remodeling complexes to associate with this small number of regulated enhancers. Overall, this work provides a detailed mechanism by which PAX3-FOXO1 maintains an oncogenic transcriptional regulatory network.
- organism: human
- assay: ChIP-seq
- assay: DNA methylation
- research focus: gene regulatory network inference
- approach: experimental assay
- Citations
- 39
- FWCI
- 2.37
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Miswired enhancer logic drives translocation positive rhabdomyosarcoma
B. E. Gryder, M. Wachtel, … J. Khan·bioRxiv·Sep 6, 2019
- Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs
L. MANCEAU, J. RICHARD ALBERT, … V. Ribes·bioRxiv·Aug 18, 2021
- Pioneer activity of an oncogenic fusion transcription factor at inaccessible chromatin
Benjamin D. Sunkel, Meng Wang, … Benjamin Z. Stanton·iSciencePeer-reviewed·Jul 16, 2021
- Integrative multi-omics analysis reveals conserved hierarchical mechanisms of FOXO3 pioneer-factor activity
A. K. Brown, S. K. Maybury-Lewis, A. E. Webb·bioRxiv·Apr 6, 2021
- Dissecting FOXA1 pioneering function by acute pharmacological degradation
Lauren M. Hargis, Paige A. Barta, … Michael A. Erb·bioRxiv·Feb 26, 2026
- Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo
Jack P. Kucinski, Alexi M Tallan, … Genevieve C. Kendall·Cell ReportsPeer-reviewed·Jul 1, 2025